Vertex Pharma receives CHMP positive opinion for label expansion of Kaftrio in combination with ivacaftor: London Tuesday, March 4, 2025, 14:00 Hrs [IST] Vertex Pharmaceuticals, a ...

With a strong foundation in CF therapies and an expanding pipeline in pain management and other areas, Vertex demonstrates solid financial health with a robust gross margin of 86.1% and revenue of ...

With a strong foundation in CF therapies and an expanding pipeline in pain management and other areas, Vertex demonstrates solid financial health with a robust gross margin of 86.1% and revenue of ...

Sionna Therapeutics recently secured an initial public offering (IPO) of $191m on the Nasdaq stock exchange, signalling ...

With a strong foundation in CF therapies and an expanding pipeline in pain management and other areas, Vertex demonstrates solid financial health with a robust gross margin of 86.1% and revenue of $11 ...

Vertex Pharmaceuticals Incorporated ( NASDAQ: VRTX) TD Cowen 45th Annual Health Care Conference Transcript March 3, 2025 3:10 PM ET David Altshuler - Executive Vice President, Global Research and CSO ...

Detailed price information for Enterprise Products Partners LP (EPD-N) from The Globe and Mail including charting and trades.

Vertex Pharmaceuticals (VRTX) stock in focus as company secures EU backing to expand label for its cystic fibrosis therapy ...

There are plenty of great investment alternatives in the healthcare sector. You won't need a boatload of money to get started ...

Vertex enjoys a monopoly with its CF therapies and has three new potential blockbusters on the market. The company's powerhouse pipeline and hefty cash stockpile could fuel more growth in the future.

Vertex’s drugs combine both mechanisms to improve CFTR function at the surface of a cell. Waltham, Massachusetts-based Sionna is developing CF drugs that target NBD1, a domain on the CFTR protein.

Learn more about whether Alnylam Pharmaceuticals, Inc. or Vertex Pharmaceuticals Incorporated is a better investment based on ...